Brokerages Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) PT at $81.67

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has received an average rating of “Moderate Buy” from the eleven analysts that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $81.6667.

ARWR has been the topic of a number of research analyst reports. Morgan Stanley boosted their price objective on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 7th. Royal Bank Of Canada raised their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 10th. Weiss Ratings upgraded shares of Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 6th. Finally, Bank of America increased their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 130,000 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $68.85, for a total value of $8,950,500.00. Following the completion of the transaction, the chief executive officer owned 3,971,255 shares of the company’s stock, valued at approximately $273,420,906.75. This represents a 3.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James C. Hamilton sold 40,164 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the transaction, the insider owned 171,958 shares of the company’s stock, valued at approximately $10,852,269.38. The trade was a 18.93% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 495,836 shares of company stock worth $32,759,810 over the last quarter. Insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ARWR. Corient Private Wealth LLC lifted its position in Arrowhead Pharmaceuticals by 3.1% during the fourth quarter. Corient Private Wealth LLC now owns 18,226 shares of the biotechnology company’s stock valued at $1,210,000 after buying an additional 551 shares during the period. Bank of Hawaii purchased a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter worth about $1,276,000. Invesco Ltd. grew its position in shares of Arrowhead Pharmaceuticals by 8.9% in the 4th quarter. Invesco Ltd. now owns 547,758 shares of the biotechnology company’s stock worth $36,366,000 after buying an additional 44,866 shares during the period. Mercer Global Advisors Inc. ADV bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth about $352,000. Finally, Summit Global Investments increased its stake in shares of Arrowhead Pharmaceuticals by 43.8% in the 4th quarter. Summit Global Investments now owns 14,287 shares of the biotechnology company’s stock worth $949,000 after acquiring an additional 4,353 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR stock opened at $55.05 on Thursday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. Arrowhead Pharmaceuticals has a fifty-two week low of $9.57 and a fifty-two week high of $76.76. The firm has a market cap of $7.71 billion, a P/E ratio of 35.98 and a beta of 1.23. The business’s 50 day moving average price is $64.47 and its 200-day moving average price is $51.36.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The business had revenue of $264.03 million for the quarter, compared to the consensus estimate of $225.66 million. During the same quarter in the prior year, the company earned ($1.39) EPS. Arrowhead Pharmaceuticals’s revenue was up 10461.3% compared to the same quarter last year. On average, equities research analysts anticipate that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.